Sangamo Therapeutics (SGMOQ) Free Cash Flow (2010 - 2025)

Sangamo Therapeutics' Free Cash Flow history runs 16 years deep, the most recent figure standing at -$24.4 million for Q4 2025.

• On a quarterly basis, Free Cash Flow fell 663.51% year-over-year to -$24.4 million in Q4 2025; TTM through Dec 2025 was -$97.3 million, a 44.43% decrease from a year earlier, with the FY2025 full-year figure at -$97.3 million, down 44.43% from the prior year.
• Free Cash Flow rose to -$24.4 million in Q4 2025 per SGMOQ's latest filing, from -$28.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $11.4 million in Q3 2024 and bottomed at -$76.5 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$51.5 million (2022), against an average of -$44.5 million.
• Across the five-year window, Free Cash Flow slumped 3121.86% in 2021 and jumped 125.19% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$55.6 million in 2021, then decreased by 16.11% to -$64.5 million in 2022, then gained by 25.25% to -$48.2 million in 2023, then surged by 93.37% to -$3.2 million in 2024, then tumbled by 663.51% to -$24.4 million in 2025.
• Per Business Quant, the three latest SGMOQ Free Cash Flow figures stand at -$24.4 million (Q4 2025), -$28.6 million (Q3 2025), and -$17.9 million (Q2 2025).